Literature DB >> 12950451

Molecular mechanism of psychosine-induced cell death in human oligodendrocyte cell line.

Ehtishamul Haq1, Shailendra Giri, Inderjit Singh, Avtar K Singh.   

Abstract

This study delineates the molecular mechanism underlying psychosine-induced oligodendroglial cell death. An immortalized human oligodendroglial cell line, MO3.13, was treated with exogenous psychosine (beta-galactosylsphingosine), a toxic metabolite that accumulates in the tissues of patients with Krabbe's disease. The mode of cell death induced by psychosine was found to be apoptotic, as revealed by different apoptotic markers viz., TUNEL, DNA fragmentation and caspase cleavage/activation. The action of psychosine was redox sensitive, as measured by changes in mitochondrial membrane potential (psidelta), and this effect of psychosine could be reversed by pre-treatment with the antioxidant molecules N-acetyl-l-cysteine or pro-cysteine. Psychosine directly affects the mitochondria as revealed by the activation of caspase 9 but not caspase 8. Up-regulation of the c-jun/c-jun N-terminal kinase pathway by psychosine leads to the induction of AP-1 and, at the same time, psychosine also down-regulates the lipopolysaccharide-induced NF-kappaB transactivation. These observations indicate that the mechanism of action of psychosine is, through the up-regulation of AP-1, a pro-apoptotic pathway as well as, through the down-regulation of the NF-kappaB pathway, an antiapoptotic pathway.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12950451     DOI: 10.1046/j.1471-4159.2003.01941.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  46 in total

1.  Factors that affect postnatal bone growth retardation in the twitcher murine model of Krabbe disease.

Authors:  Miguel Agustin Contreras; William Louis Ries; Srinivasan Shanmugarajan; Gonzalo Arboleda; Inderjit Singh; Avtar Kaur Singh
Journal:  Biochim Biophys Acta       Date:  2010-05-02

Review 2.  Lysosphingolipids and sphingolipidoses: Psychosine in Krabbe's disease.

Authors:  Stefka Spassieva; Erhard Bieberich
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

Review 3.  Newborn screening for Krabbe's disease.

Authors:  Joseph J Orsini; Carlos A Saavedra-Matiz; Michael H Gelb; Michele Caggana
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

Review 4.  Treatment for Krabbe's disease: Finding the combination.

Authors:  Christina R Mikulka; Mark S Sands
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

Review 5.  A microglial hypothesis of globoid cell leukodystrophy pathology.

Authors:  Alexandra M Nicaise; Ernesto R Bongarzone; Stephen J Crocker
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

Review 6.  Biochemical, cell biological, pathological, and therapeutic aspects of Krabbe's disease.

Authors:  Je-Seong Won; Avtar K Singh; Inderjit Singh
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

Review 7.  Linking mitochondrial dysfunction to neurodegeneration in lysosomal storage diseases.

Authors:  Afshin Saffari; Stefan Kölker; Georg F Hoffmann; Darius Ebrahimi-Fakhari
Journal:  J Inherit Metab Dis       Date:  2017-05-05       Impact factor: 4.982

8.  Role of endogenous psychosine accumulation in oligodendrocyte differentiation and survival: implication for Krabbe disease.

Authors:  Je-Seong Won; Jinsu Kim; Manjeet Kaur Paintlia; Inderjit Singh; Avtar K Singh
Journal:  Brain Res       Date:  2013-02-21       Impact factor: 3.252

Review 9.  Peroxisomal dysfunction in inflammatory childhood white matter disorders: an unexpected contributor to neuropathology.

Authors:  Inderjit Singh; Avtar K Singh; Miguel A Contreras
Journal:  J Child Neurol       Date:  2009-07-15       Impact factor: 1.987

10.  Oxidative stress as a therapeutic target in globoid cell leukodystrophy.

Authors:  Jacqueline A Hawkins-Salsbury; Elizabeth Y Qin; Adarsh S Reddy; Carole A Vogler; Mark S Sands
Journal:  Exp Neurol       Date:  2012-07-28       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.